Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;8(4):1557-1562.
doi: 10.3892/ol.2014.2323. Epub 2014 Jul 7.

Interfering with CXCR4 expression inhibits proliferation, adhesion and migration of breast cancer MDA-MB-231 cells

Shanyu Guo  1 , Dan Xiao  1 , Huihui Liu  1 , Xiao Zheng  1 , Lei Liu  1 , Shougui Liu  1
Affiliations

Interfering with CXCR4 expression inhibits proliferation, adhesion and migration of breast cancer MDA-MB-231 cells

Shanyu Guo et al. Oncol Lett. 2014 Oct.

Abstract

To investigate the effect and mechanism of the CXC chemokine receptor 4 (CXCR4) in the proliferation and migration of breast cancer, a short-hairpin RNA (shRNA) eukaryotic expression vector targeting CXCR4 was constructed, and the impact of such on the proliferation, adhesion and migration of human breast cancer MDA-MB-231 cells was observed. The fragments of CXCR4-shRNA were synthesized and cloned into a pGCsi-U6-Neo-green fluorescent protein vector. The recombinant plasmids were transfected into 293T cells and the most efficacious interfering vector was selected. MDA-MB-231 cells were transfected by liposome assay. The effects of silencing CXCR4 expression by shRNA on the growth, adhesion and migration of MDA-MB-231 cells were determined by Cell Counting Kit-8, cell-matrix adhesion and wound-healing assays. The shRNA eukaryotic expression vectors targeting CXCR4 (CXCR4-shRNA) were successfully constructed and transfected into 293T cells. Quantitative polymerase chain reaction and western blot analysis revealed that the maximum inhibitory rate of CXCR4 expression was 81.3%. CXCR4-shRNA transfection significantly inhibited the proliferation of MDA-MB-231 cells (P<0.05), as well as the adhesion between MDA-MB-231 cells and the extracellular matrix (P<0.05). Furthermore, wound-healing assays demonstrated that the migration distance of MDA-MB-231 cells in the CXCR4-shRNA transfection group was significantly smaller than that in the control plasmid and blank control groups (P<0.01). The CXCR4-shRNA interfering vector specifically inhibited CXCR4 expression, as well as the proliferation, adhesion and migration of MDA-MB-231 cells.

Keywords: CXC chemokine receptor 4; RNA interference; breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Identification of recombinant CXCR4 interfering RNA plasmid by restriction enzyme digestion. M, marker; 1, pGCsi-CXCR4-1/ShRNA; 2, pGCsi-CXCR4-2/ShRNA; and 3, negative control. CXCR4, CXC chemokine receptor 4.
Figure 2
Figure 2
Transfection efficiency of interfering RNA CXCR4 vector in 293T cells (magnification, ×100). (A) pGCsi-CXCR4-1/ShRNA, (B) pGCsi-CXCR4-2/ShRNA and (C) negative control. CXCR4, CXC chemokine receptor 4.
Figure 3
Figure 3
(A) mRNA and (B) protein expression of CXCR-4 in 239T cells by RNA interference. 1, pGCsi-CXCR4-1/ShRNA; 2, pGCsi-CXCR4-2/ShRNA; 3, negative control; and 4, blank control. CXCR4, CXC chemokine receptor 4.
Figure 4
Figure 4
Silencing CXCR4 expression inhibits the proliferation of MDA-MB-231 cells. *P<0.05, vs. negative control or blank control. 1, pGCsi-CXCR4-1/ShRNA; 2, negative control; and 3, blank control. CXCR4, CXC chemokine receptor 4.
See this image and copyright information in PMC

References

    1. Sellers TA. Genetic factors in the pathogenesis of breast cancer: their role and relative importance. J Nutr. 1997;27(5 Suppl):929S–932S. - PubMed
    1. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285–293. - PMC - PubMed
    1. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–S8. - PubMed
    1. Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71:1871–1882. - PMC - PubMed
    1. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer - much more than directing cell movement. Int J Dev Biol. 2004;48:489–496. - PubMed

LinkOut - more resources